FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula 1, where X represents a C1-C4 alkylsulfonyl group, Y2 and Y3 each independently represents a C1-C4 alkyl group, unsubstituted or substituted with deuterium, and Y1 represents a methyl group substituted by one or more atoms of deuterium, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for the treatment of lung cancer, including the specified compound, is also proposed.
EFFECT: compound represented by Formula 1 effectively inhibits the growth of ALK-mutated and EGFR-mutated cancer cells.
7 cl, 4 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PYRIMIDINE DERIVATIVE WITH AN EFFECT OF INHIBITING GROWTH OF CANCER CELLS AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2744168C1 |
| PYRIMIDINE DERIVATIVE THAT SUPPRESSES CANCER CELL GROWTH AND MEDICAL APPLICATION THEREOF | 2020 |
|
RU2792849C1 |
| PYRROLO-PYRIDINE COMPOUND DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING PROTEIN KINASE RELATED DISEASES | 2018 |
|
RU2730849C1 |
| DYETERED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH CONNECTIONS | 2014 |
|
RU2632907C2 |
| SUBSTITUTED N2-(4-AMINO-2-METHOXYPHENYL)-N4-[2-(DIMETHYLPHOSPHORYL)-PHENYL]-5-CHLORO-PYRIMIDINE-2,4-DIAMINES AS MODULATORS OF ALK AND EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2607371C1 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
| DIAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | 2010 |
|
RU2526253C2 |
| COMPOUNDS WITH SPIRO AND AROMATIC RINGS AND APPLICATION THEREOF | 2019 |
|
RU2781100C1 |
| 8-(1-{4-{(5-CHLORO-4-{(2-(DIMETHYLPHOSPHORYL)PHENYL)AMINO}PYRIMIDIN-2-YL)AMINO)-3-METHOXYPHENYL}PIPERIDIN-4-YL)-1-METHYL-1,8-DIAZASPIRO(4.5)DECAN-2-ONE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS AN ALK AND EGER MODULATOR FOR TREATMENT OF CANCER | 2017 |
|
RU2654695C1 |
